[Adrenergic activation in heart failure: blockade or rebalance?].
Emdin
Michele
M
Vergaro
Giuseppe
G
Giannoni
Alberto
A
Passino
Claudio
C
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology*; D006339:Heart Rate; D006706:Homeostasis; D006801:Humans; D009200:Myocardial Contraction; D020932:Nerve Growth Factor / Q000502:physiology / Q000627:therapeutic use; D009638:Norepinephrine / Q000097:blood; D011943:Receptors, Adrenergic, beta; D013564:Sympathetic Nervous System / Q000502:physiology*; D013997:Time Factors; D015854:Up-Regulation; D018754:Ventricular Dysfunction / Q000503:physiopathology; D020257:Ventricular Remodeling / Q000502:physiology
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D011943:Receptors, Adrenergic, beta; D020932:Nerve Growth Factor; D009638:Norepinephrine